Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Lymphoma Diagnosis and Treatment Center of Henan Province, Zhengzhou, Henan, China.
J Cancer Res Clin Oncol. 2022 Dec;148(12):3449-3459. doi: 10.1007/s00432-022-04203-x. Epub 2022 Jul 20.
To investigate the clinical characteristics and prognostic factors of natural killer/T-cell lymphoma (NKTCL).
We retrospectively reviewed 410 NKTCL patients admitted to our lymphoma center from 2000 to 2019. Overall survival (OS) and progression-free survival (PFS) were estimated with the Kaplan-Meier method, and the differences between the study groups were compared by the log-rank test.
The median age of the 410 patients was 44 (range 8-84), and the 5-year OS and PFS were 61.2% and 38.4%, respectively. For patients with stage I/II, the 5-year PFS rate was 57.5%, and the 5-year OS rate was 77.2%. For patients with stage III/IV, the 5-year PFS rate was 17.4%, and the 5-year OS rate was 43.7%. Compared to the patients who received radiotherapy alone or chemotherapy alone as their initial treatment, the patients who received combined chemoradiotherapy had longer PFS (P = 0.013). Independent prognostic factors for OS were stage III/IV (P = 0.001), elevated IPI/aaIPI score (P = 0.019), elevated PINK score (P < 0.001) and elevated plasma EBV-DNA (P = 0.003). An elevated PINK score (P < 0.001) was an independent prognostic factor for PFS.
Stage III/IV, elevated IPI/aaIPI score, elevated PINK score and elevated plasma EBV-DNA were independent prognostic factors for OS. Elevated PINK score was an independent prognostic factor for PFS. In stage III/IV patients, the patients who received combined chemoradiotherapy had significantly longer PFS.
探讨自然杀伤/T 细胞淋巴瘤(NKTCL)的临床特征和预后因素。
我们回顾性分析了 2000 年至 2019 年期间在我们淋巴瘤中心就诊的 410 例 NKTCL 患者。采用 Kaplan-Meier 法估计总生存期(OS)和无进展生存期(PFS),采用对数秩检验比较研究组之间的差异。
410 例患者的中位年龄为 44 岁(范围 8-84 岁),5 年 OS 和 PFS 分别为 61.2%和 38.4%。对于Ⅰ/Ⅱ期患者,5 年 PFS 率为 57.5%,5 年 OS 率为 77.2%。对于Ⅲ/Ⅳ期患者,5 年 PFS 率为 17.4%,5 年 OS 率为 43.7%。与单独接受放疗或化疗作为初始治疗的患者相比,接受联合放化疗的患者 PFS 更长(P=0.013)。OS 的独立预后因素为Ⅲ/Ⅳ期(P=0.001)、IPI/aaIPI 评分升高(P=0.019)、PINK 评分升高(P<0.001)和血浆 EBV-DNA 升高(P=0.003)。PINK 评分升高(P<0.001)是 PFS 的独立预后因素。
Ⅲ/Ⅳ期、IPI/aaIPI 评分升高、PINK 评分升高和血浆 EBV-DNA 升高是 OS 的独立预后因素。PINK 评分升高是 PFS 的独立预后因素。在Ⅲ/Ⅳ期患者中,接受联合放化疗的患者 PFS 显著更长。